Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project

Inge M.W. Verberk*, Heleen M.A. Hendriksen, Argonde C. van Harten, Linda M.P. Wesselman, Sander C.J. Verfaillie, Karlijn A. van den Bosch, Rosalinde E.R. Slot, Niels D. Prins, Philip Scheltens, Charlotte E. Teunissen, Wiesje M. Van der Flier

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Plasma biomarkers are promising prognostic tools in individuals with subjective cognitive decline (SCD). We aimed to investigate the relationships of baseline plasma amyloid beta (Aβ)42/Aβ40 and total Tau (tTau) with rate of cognitive decline, in comparison to relationships of baseline cerebrospinal fluid (CSF) Aβ42, tTau, and phosphorylated tau181 (pTau181) with rate of cognitive decline. We included 241 subjects with SCD (age = 61 ± 9, 40% female, Mini-Mental State Examination = 28 ± 2) with follow-up (average: 2 ± 2 years, median visits: 3 [range: 1–11]) for re-evaluation of neuropsychological test performance (attention, memory, language, and executive functioning domains). Using age, gender and education-adjusted linear mixed models, we found that lower plasma Aβ42/Aβ40 was associated with steeper rate of decline on tests for attention, memory, and executive functioning, but not language. Lower CSF Aβ42 was associated with steeper decline on tests covering all domains. Associations for plasma amyloid and cognitive decline mirror those of CSF amyloid. Plasma tTau was not associated with rate of cognitive decline, whereas CSF tTau and pTau181 were on multiple tests covering all domains.

Original languageEnglish
Pages (from-to)99-107
Number of pages9
JournalNeurobiology of Aging
Early online date1 Jan 2020
Publication statusPublished - May 2020

Cite this